Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.
Meeting Details:
Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting
Date: June 8 – June 11, 2024
Location: Metro Toronto Convention Centre, Toronto, ON, Canada